COVID-19
Conditions
Keywords
COVID-19, immunoglobulin, COVID-HIG, SARS-CoV-2, 2019nCov, hyperimmune globulin, Coronavirus disease 2019, passive immunotherapy, therapeutic
Brief summary
A randomized, double-blind, placebo-controlled phase II exploratory clinical trial to evaluate the efficacy and safety of Human COVID-19 immunoglobulin (pH4) for intravenous injection (COVID-HIG) in the treatment of patients with COVID-19.
Detailed description
Eligible adault patients with confirmed COVID-19 will be randomized 1:1:1 to receive intravenous injections of High-dose COVID-HIG, Low-dose COVID-HIG or Placebo ( 0.9% sodium chloride injection). Patients in each arm will receive continued standard of care (SOC) therapy. The primary efficacy end point is the median time to clinical improvement (defined as clinical improvement of at least 2 points from baseline on the 7-point ordinal scale) observed from 0 to 28 days after the first administration.
Interventions
BIOLOGICALHuman COVID-19 immunoglobulin (pH4) for intravenous injection
The initial infusion rate is 0.01 \ 0.02 ml/kg body weight/minute (1ml is about 20 drops). If there was no adverse reaction after 15 minutes, the infusion rate could be gradually accelerated. However, it should not exceed 0.08 ml/kg body weight/minute.
DRUGPlacebo
The initial infusion rate is 0.01 \ 0.02 ml/kg body weight/minute (1ml is about 20 drops). If there was no adverse reaction after 15 minutes, the infusion rate could be gradually accelerated. However, it should not exceed 0.08 ml/kg body weight/minute
Sponsors
China National Biotec Group Company Limited
Beijing Tiantan Biological Products Co., Ltd.
Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. ≥18 and \<65 years of age when signing the ICF, male or femal. 2. Positive testing by virologic test (SARS-CoV-2 virus nucleic acid test,result of RT-PCR within 3 days are accpetable) before randomization. 3. COVID-19 related clinical symptoms (fever or respiratory symptoms, etc.) progresses before randomization. 4. Inpatients with moderate or severe COVID-19 (severity is graded by FDA standard). 5. With early warning signs for severe/critical cases, meet any of the following indicators: ①Progressive exacerbation of hypoxemia or respiratory distress; ②Deterioration of tissue oxygenation or progressive hyperlactatemia. ③ Rapid decrease in lymphocyte count or steady increase in inflammatory markers such as IL-6, CRP, and ferritin. ④Significant increase of D-dimer and other related indexes of coagulation function. ⑤Chest imaging showing rapid progression of lung lesions. 6. Randomization should be within 10 days of COVID-19 symptoms onset. 7. Subjects (including their partners) have no pregnancy plan and voluntarily take effective contraceptive measures from signing ICF to 3 months after he/she finished the trial. 8. Willing to comply with the requirements, and cooperate when collecting of nasopharyngeal swabs and venous blood for testing according to the protocol; and willing to complete the study. 9. Able to consent, and willing to sign the ICF.
Exclusion criteria
1. Asymptomatic infection, mild or critical COVID-19. 2. SP02 \< 93% under high-flow oxygen inhalation, or receiving of invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO). 3. Reinfected subjects with historical confirmed COVID-19, detectable by SARS-CoV-2 serological test (nasopharyngeal SARS-CoV-2 RNA levels or serum antibody). 4. May be transferred to another hospital, that is not one of the trial sites, within 72 hours. 5. Meets one of the following high-risk factors: a) Pre-existing cardiovascular (including uncontrolled hypertension: SBP≥ 160 mmHg and/or DBP≥ 100 mmHg) and cerebrovascular diseases, chronic lung diseases (chronic obstructive pulmonary disease (COPD), moderate to severe asthma), diabetes (HbA1c \> 9.0%), chronic liver diseases, chronic kidney diseases, malignancies or other complicated diseases. b) Pre-existing Immunosuppression (such as AIDS, long-term use of corticosteroids or other immunosuppressive drugs that lead to a weakened immune function). c) Obesity: body mass index ≥ 35. d) Heavy smokers: ≥20 cigarettes per day on average. 6. History of allergic to IVIG, other plasma proteins or blood products, history of selective IgA deficiency with presence of anti-IgA antibodies. 7. Vaccinated in last 8 weeks, such as influenza, poliomyelitis, measles, rubella, mumps and varicella virus vaccines. 8. May worsen and progress to critical COVID-19 rapidly. 9. Useage of other antiviral drugs to treat SARS-CoV-2 (except the basic treatment specified in the protocol) before randomization. 10. History of major surgery (defined as life-threatening surgery, requiring general anesthesia and causing severe bleeding, including bone and joint surgery on elbow, shoulder, hip, knee, ankle and spine) within 8 weeks before screening (including 8 weeks), or plan to surgery during the trial, which may bring unacceptable risks to the subjects, evaluation by investigators. 11. ALT or AST \> 2 times of the normal range upper limit, or Ccr \< 60 ml/min. 12. D-dimer increased significantly (\> 1 mg/L); History of thromboembolism or coagulation diseases in last 1 year, such as acute coronary syndrome, cerebrovascular syndrome, pulmonary or deep vein thrombosis, etc. 13. Positive of virues makers ( positive of HBsAg, HCV-Ab, or Treponema pallidum specific antibody). 14. History of organ transplantation (such as heart, lung, liver, kidney, etc. 15. Pregnant or lactating female. 16. Other subjects who are not suitable to participate in the trial considered by the investigator, such as potential compliance problems, can not complete all the examinations and evaluations according to the protocol, mental illness, obvious mental disorders; Incapacity or cognitive ability caused by other reasons. 17. History of participated in other investigate drugs or medical devices clinical trials in last 1 month before signing ICF.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time to clinical improvement | within 28 days | The primary efficacy end point is the median time to clinical improvement (defined as clinical improvement of at least 2 points from baseline on the 7-point ordinal scale) observed from 0 to 28 days after the first administration. 1. Death 2. Hospitalized, receiving Invasive mechanical ventilation or ECMO 3. Hospitalized, receiving non-invasive ventilation or high-flow oxygen devices 4. Hospitalized, requiring Low flow supplemental oxygen 5. Hospitalized, not requiring oxygen- but receiving ongoing medical care (related or not related to COVID-19) 6. Hospitalized/not hospitalized, Requiring neither oxygen nor ongoing medical care (other than that specified in the the protocol for COVID-HIG adminstration) 7. Not hospitalized, discharge or prepare for discharge from a healthcare facility |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes of 7-point ordinal scale for COVID-19 clinical improvement | 7 days, 14 days, and 28 days | Compare the clinical status of subjects in each group on day 7, 14, and 28 after the first administration using the primary 7-point ordinal outcome scale. Outcome is reported as the percent of subjects in each of 7 categories and changes in each group compared with baseline. |
| COVID-19-Related Symptoms | 1 day, 3 days, 5 days, 7 days and 14 days | Outcome is reported as changes in each group compared with baseline. |
| Discharge Status | 7 days, 14 days, and 28 days | Outcome is reported as the percent of subjects in each arm who discharged at day 7, 14, and 28 post treatment. |
| Length of hospital stay | within 28 days | Number of days between the first administration and discharge. |
| All-cause Mortality | within 28 days | Outcome is reported as the all-cause mortality within 28 days of each arm. |
| Treatment in ICU | within 28 days | The proportion and number of subjects who need treatment in ICU within 28 days after the first administration. |
| Changes of leukocyte count, lymphocyte count, C-reactive protein, IL-6 and SARS-CoV-2 nucleic acid (quantitative) | 1 day, 3 days, 5days, 7 days, 14 days | Outcome is reported as the changes of leukocyte count, lymphocyte count, C-reactive protein, IL-6, and SARS-CoV-2 nucleic acid (quantitative) on 1day, 3days, 5days, 7 days, and 14 days commpared with baseline. |
| SARS-CoV-2 Neutralizing Antibody Level | 1 day, 3 days, 7 days, and 28 days | Outcome reported as the changes in anti-SARS-CoV-2 neutralizing antibody titer in blood from baseline to 1 day, 3 days, 7 days, and 28 days post treatment. Outcome is reported in units of antibody titer. |
| Glucocorticoid therapy | within 28 days | The proportion and the number of subjects receiving glucocorticoid therapy within 28 days after the first administration. |
| Rate of worsening | within 28 days | Worsening is defined as the 2 least favorable categories on the primary ordinal scale. Outcome is reported as the percent of subjects in each arm who are characterized as worsening within 28 days post treatment. |
| Finger oxygen saturation | 1 day, 3 days, 5 days, 7 days, 14 days, and 28 days | Change of finger oxygen saturation compared with the baseline. |
| Negativization rate of SARS-CoV-2 nucleic acid | within 72 hrs (24 hrs, 48 hrs, 72 hrs), 7 days, 14 days, and 28 days | Outcome is reported as the percent of subjects with negative results in each arm. |
Countries
United Arab Emirates
Contacts
Primary ContactYunKai Yang, Prof
Outcome results
None listed